A new pancreatic cancer drug is now being offered to patients outside of clinical trials. Daraxonrasib is an experimental pill that doubled survival time compared to standard chemotherapy, according to the results of a clinical trial.
Ed Silverman, a columnist and senior writer at STAT, joins us to discuss what this new drug means for pancreatic cancer patients.
This article was originally published on WBUR.org.
Copyright 2026 WBUR
